Seelos Therapeutics Inc. [SEEL] is 18.99% higher this YTD. Is it still time to buy?

Related

Share

Seelos Therapeutics Inc. [NASDAQ: SEEL] plunged by -$0.07 during the normal trading session on Wednesday and reaching a high of $2.115 during the day while it closed the day at $1.88. The company report on November 24, 2021 that iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products.

iX Biopharma will receive an initial US$9 million upfront payment.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Eligible for up to US$239 million in development and sales milestone payments.

Seelos Therapeutics Inc. stock has also loss -10.48% of its value over the past 7 days. However, SEEL stock has declined by -9.62% in the 3 months of the year. Over the past six months meanwhile, it has lost -42.51% and gained 18.99% year-on date.

The market cap for SEEL stock reached $195.48 million, with 102.33 million shares outstanding and 97.38 million shares in the current float. Compared to the average trading volume of 3.84M shares, SEEL reached a trading volume of 6041743 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Seelos Therapeutics Inc. [SEEL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SEEL shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SEEL stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Seelos Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 27, 2021. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on July 01, 2021, representing the official price target for Seelos Therapeutics Inc. stock. Previously, the target price had yet another raise to $10, while Cantor Fitzgerald analysts kept a Overweight rating on SEEL stock.

The Average True Range (ATR) for Seelos Therapeutics Inc. is set at 0.15 The Price to Book ratio for the last quarter was 2.65, with the Price to Cash per share for the same quarter was set at 0.74.

SEEL stock trade performance evaluation

Seelos Therapeutics Inc. [SEEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.48. With this latest performance, SEEL shares dropped by -13.36% in over the last four-week period, additionally sinking by -42.51% over the last 6 months – not to mention a rise of 118.60% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 37.10, with the RSI for the last a single of trading hit 34.15, and the three-weeks RSI is set at 39.96 for Seelos Therapeutics Inc. [SEEL]. The present Moving Average for the last 50 days of trading for this stock 2.1968, while it was recorded at 1.8960 for the last single week of trading, and 3.1245 for the last 200 days.

Seelos Therapeutics Inc. [SEEL]: An insightful look at the core fundamentals

Return on Total Capital for SEEL is now -305.30, given the latest momentum, and Return on Invested Capital for the company is -387.52. Return on Equity for this stock declined to -1,489.36, with Return on Assets sitting at -133.62. When it comes to the capital structure of this company, Seelos Therapeutics Inc. [SEEL] has a Total Debt to Total Equity ratio set at 378.07. Additionally, SEEL Total Debt to Total Capital is recorded at 79.08, with Total Debt to Total Assets ending up at 55.58. Long-Term Debt to Equity for the company is recorded at 283.55, with the Long-Term Debt to Total Capital now at 59.31.

Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc. [SEEL] managed to generate an average of -$1,910,100 per employee.Seelos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.10 and a Current Ratio set at 10.10.

Earnings per share (EPS) analysis for Seelos Therapeutics Inc. [SEEL] stock

With the latest financial reports released by the company, Seelos Therapeutics Inc. posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SEEL.

>> 7 Top Picks for the Post-Pandemic Economy <<

Seelos Therapeutics Inc. [SEEL]: Insider Ownership positions

There are presently around $78 million, or 41.10% of SEEL stock, in the hands of institutional investors. The top three institutional holders of SEEL stocks are: BLACKROCK INC. with ownership of 6,382,949, which is approximately 19.49% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 5,177,503 shares of the stock with an approximate value of $10.1 million in SEEL stocks shares; and WOODLINE PARTNERS LP, currently with $8.54 million in SEEL stock with ownership of nearly 43.849% of the company’s market capitalization.

Positions in Seelos Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 62 institutional holders increased their position in Seelos Therapeutics Inc. [NASDAQ:SEEL] by around 6,597,890 shares. Additionally, 44 investors decreased positions by around 7,277,134 shares, while 22 investors held positions by with 26,283,086 shares. The mentioned changes placed institutional holdings at 40,158,110 shares, according to the latest SEC report filing. SEEL stock had 23 new institutional investments in for a total of 1,200,398 shares, while 18 institutional investors sold positions of 2,266,929 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam